The use of omalizumab for treatment‐refractory chronic spontaneous urticaria in a West Australian outpatient cohort

There is a lack of real‐world data on the use of omalizumab in treatment‐refractory chronic spontaneous urticaria (CSU). A single‐centre retrospective cohort study was performed to assess the efficacy and safety of omalizumab for treatment‐refractory CSU. The overall response rate of 67% is comparab...

Full description

Saved in:
Bibliographic Details
Published in:Internal medicine journal 2019-04, Vol.49 (4), p.526-528
Main Authors: Farrah, Georgia, Stevenson, Brittany, Lie, Katie, Brusch, Anna
Format: Article
Language:English
Subjects:
Adult
Aged
Anti-Allergic Agents - therapeutic use
chronic spontaneous urticaria
Chronic Urticaria - drug therapy
Disease control
Female
Humans
Immunoglobulin E
Immunotherapy
Male
Middle Aged
Monoclonal antibodies
omalizumab
Omalizumab - therapeutic use
Remission
Remission Induction
Retreatment
Retrospective Studies
safety
treatment
Treatment Outcome
treatment‐refractory
Urticaria
Western Australia
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is a lack of real‐world data on the use of omalizumab in treatment‐refractory chronic spontaneous urticaria (CSU). A single‐centre retrospective cohort study was performed to assess the efficacy and safety of omalizumab for treatment‐refractory CSU. The overall response rate of 67% is comparable with that reported in the literature. Disease control and sustained remission can be achieved with omalizumab, even in patients with treatment‐resistant CSU.
ISSN:1444-0903
1445-5994
DOI:10.1111/imj.14245